1. Home
  2. DHF vs SLGL Comparison

DHF vs SLGL Comparison

Compare DHF & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BNY Mellon High Yield Strategies Fund

DHF

BNY Mellon High Yield Strategies Fund

N/A

Current Price

$2.21

Market Cap

160.0M

Sector

Finance

ML Signal

N/A

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$54.16

Market Cap

180.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DHF
SLGL
Founded
N/A
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.0M
180.5M
IPO Year
1998
2016

Fundamental Metrics

Financial Performance
Metric
DHF
SLGL
Price
$2.21
$54.16
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $155.50
AVG Volume (30 Days)
★ 529.4K
28.9K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$34.47
52 Week High
$2.57
$97.97

Technical Indicators

Market Signals
Indicator
DHF
SLGL
Relative Strength Index (RSI) 45.76 30.46
Support Level $2.16 N/A
Resistance Level $2.23 $81.68
Average True Range (ATR) 0.03 4.19
MACD -0.00 -0.95
Stochastic Oscillator 12.67 17.43

Price Performance

Historical Comparison
DHF
SLGL

About DHF BNY Mellon High Yield Strategies Fund

BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: